| Dokumendiregister | Ravimiamet |
| Viit | REP-1/5620-2 |
| Registreeritud | 24.10.2025 |
| Sünkroonitud | 27.10.2025 |
| Liik | Väljaminev kiri |
| Funktsioon | REP Euroopa Farmakopöaga seotud asjaajamine |
| Sari | REP-1 Euroopa Farmakopöa alane kirjavahetus |
| Toimik | REP-1/2025 |
| Juurdepääsupiirang | Avalik |
| Juurdepääsupiirang | |
| Adressaat | European Directorate for the Quality of Medicines & HealthCare |
| Saabumis/saatmisviis | European Directorate for the Quality of Medicines & HealthCare |
| Vastutaja | Signe Leito (RA, Peadirektori asetäitja valdkond, Labor) |
| Originaal | Ava uues aknas |
Addition to the work programme P4: Cariprazine hydrochloride and Cariprazine hydrochloride capsules
page 1 / 3
Q1-4 (4425)
NPA: (55286) Type: (!/list-dropdown)
A10 - Estonia (EE)
Please inform if you are in favour of the addition of Cariprazine hydrochloride to the work
programme:
(55287) Type: (L/list-radio)
In favour of the addition of Cariprazine hydrochloride to the work programme
A1
If opposed to this addition to the work programme, please state why. (55288) Type: (T/text-long)
-
page 2 / 3
Please inform if you are in favour of the addition of Cariprazine hydrochloride capsules to the
work programme:
(55290) Type: (L/list-radio)
In favour of the addition of Cariprazine hydrochloride capsules to the work programme
A1
If opposed to this addition to the work programme, please state why. (55289) Type: (T/text-long)
-
Remarks: (55291) Type: (T/text-long)
-
Powered by TCPDF (www.tcpdf.org)
page 3 / 3
| Nimi | K.p. | Δ | Viit | Tüüp | Org | Osapooled |
|---|---|---|---|---|---|---|
| Farmakopöa töökava asjus | 24.10.2025 | 3 | REP-1/5620-1 | Sissetulev kiri | ra | European Directorate for the Quality of Medicines & HealthCare |